SG11202102126VA - Alternative processes for the preparation of tubulysins and intermediates thereof - Google Patents

Alternative processes for the preparation of tubulysins and intermediates thereof

Info

Publication number
SG11202102126VA
SG11202102126VA SG11202102126VA SG11202102126VA SG11202102126VA SG 11202102126V A SG11202102126V A SG 11202102126VA SG 11202102126V A SG11202102126V A SG 11202102126VA SG 11202102126V A SG11202102126V A SG 11202102126VA SG 11202102126V A SG11202102126V A SG 11202102126VA
Authority
SG
Singapore
Prior art keywords
tubulysins
intermediates
preparation
alternative processes
alternative
Prior art date
Application number
SG11202102126VA
Other languages
English (en)
Inventor
Kun-Liang Wu
Qingwu Jin
Wendel Doubleday
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of SG11202102126VA publication Critical patent/SG11202102126VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202102126VA 2018-09-07 2019-09-06 Alternative processes for the preparation of tubulysins and intermediates thereof SG11202102126VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862728639P 2018-09-07 2018-09-07
PCT/US2019/050023 WO2020051503A1 (fr) 2018-09-07 2019-09-06 Procédés alternatifs pour la préparation de tubulysines et intermédiaires de celles-ci

Publications (1)

Publication Number Publication Date
SG11202102126VA true SG11202102126VA (en) 2021-04-29

Family

ID=68000124

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102126VA SG11202102126VA (en) 2018-09-07 2019-09-06 Alternative processes for the preparation of tubulysins and intermediates thereof

Country Status (16)

Country Link
US (1) US20230002440A1 (fr)
EP (1) EP3847161A1 (fr)
JP (1) JP7511543B2 (fr)
KR (1) KR20210073525A (fr)
CN (1) CN112996778A (fr)
AU (1) AU2019336231A1 (fr)
BR (1) BR112021004317A2 (fr)
CA (1) CA3111149A1 (fr)
EA (1) EA202190699A1 (fr)
IL (1) IL281090A (fr)
MA (1) MA53550A (fr)
MX (1) MX2021002570A (fr)
SA (1) SA521421375B1 (fr)
SG (1) SG11202102126VA (fr)
TW (1) TWI825169B (fr)
WO (1) WO2020051503A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723671C (fr) * 2007-05-10 2018-06-19 R & D Biopharmaceuticals Gmbh Derives de tubulysine
IT1394860B1 (it) 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
WO2017096311A1 (fr) 2015-12-04 2017-06-08 Seattle Genetics, Inc. Conjugués de composés de tubulysine quaternisés
CA3073766A1 (fr) 2017-09-08 2019-03-14 Seattle Genetics, Inc. Procede de preparation de tubulysines et d'intermediaires de celles-ci

Also Published As

Publication number Publication date
TW202024043A (zh) 2020-07-01
CA3111149A1 (fr) 2020-03-12
MA53550A (fr) 2021-12-15
MX2021002570A (es) 2021-06-08
IL281090A (en) 2021-04-29
SA521421375B1 (ar) 2024-02-11
JP2021536475A (ja) 2021-12-27
AU2019336231A1 (en) 2021-03-18
WO2020051503A1 (fr) 2020-03-12
US20230002440A1 (en) 2023-01-05
KR20210073525A (ko) 2021-06-18
EP3847161A1 (fr) 2021-07-14
CN112996778A (zh) 2021-06-18
BR112021004317A2 (pt) 2021-05-25
TWI825169B (zh) 2023-12-11
JP7511543B2 (ja) 2024-07-05
EA202190699A1 (ru) 2021-06-08

Similar Documents

Publication Publication Date Title
ZA201902968B (en) Method for increasing the secretion levels of interleukin 2 and proteins derived from it
IL292648A (en) A process for the preparation of glucuronide-drug binders and their intermediates
EP3433278A4 (fr) Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
IL280922A (en) Anti-HER2 polypeptides and uses thereof
ZA202101214B (en) Process and intermediates for the preparation of bilastine
IL283948A (en) Methods for treating depression
ZA202003590B (en) Process for the preparation of opicapone and intermediates thereof
PT3458467T (pt) Processo para a epoxidação 6,7-alfa de esteroide-4,6-dienos
HUE062956T2 (hu) Eljárások niraparib és köztitermékei elõállítására
IL272837A (en) A process for preparing tubolysins and their intermediates
EP3717456A4 (fr) Procédé de préparation de roxadustat et de ses intermédiaires
IL275655A (en) A process for the preparation of amino-pyrimidine and its intermediates
HUE058259T2 (hu) Eljárás lubiproszton és annak intermedierei elkészítésére
PL3737685T3 (pl) Sposób wytwarzania kryzaborolu i jego związków pośrednich
GB201915447D0 (en) Polymorphs of avapritinib and methods of preparing the polymorphs
IL281090A (en) Alternative processes for the preparation of tubolysins and their intermediates
IL255819A (en) An improved process for the preparation of sofosbuvir and intermediates
IL290169A (en) Method and intermediates for the preparation of pyroxulfone
ZA202107053B (en) Novel process for the preparation of filgotinib and intermediates thereof
IL278549B1 (en) Intermediates and processes for the preparation of linagliptin and its salts
EP3877361C0 (fr) Procédé de préparation d'arylsulfonylpropènenitriles
PT3969459T (pt) Processo e intermediários para a preparação de eldecalcitol
LT4073051T (lt) Būdas ir tarpinis junginys, skirti oksetan-2-ilmetanamino gavimui
PL3704100T3 (pl) Nowy sposób wytwarzania tawaborolu i jego związków pośrednich
HUP1500451A2 (en) Processes for the preparation of 1,4,7-triaza-cyclononane derivatives and intermediates